Indivior Pharmaceuticals, Inc. (DELISTED) (INDV:DL)
36.28
+0.91
(+2.57%)
USD |
NASDAQ |
Nov 02, 16:00
Indivior Pharmaceuticals SG&A Expense (TTM) : 555.00M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 555.00M |
| June 30, 2026 | 591.00M |
| March 31, 2026 | 627.00M |
| December 31, 2025 | 635.00M |
| September 30, 2025 | 623.00M |
| June 30, 2025 | 675.00M |
| March 31, 2025 | 828.00M |
| December 31, 2024 | 841.00M |
| September 30, 2024 | 821.00M |
| June 30, 2024 | 1.003B |
| March 31, 2024 | 825.00M |
| December 31, 2023 | 811.00M |
| September 30, 2023 | 1.086B |
| June 30, 2023 | 811.00M |
| March 31, 2023 | 787.00M |
| December 31, 2022 | 765.00M |
| September 30, 2022 | 402.00M |
| June 30, 2022 | 345.00M |
| March 31, 2022 | 277.00M |
| December 31, 2021 | 210.00M |
| September 30, 2021 | 242.00M |
| June 30, 2021 | 241.00M |
| March 31, 2021 | 259.00M |
| December 31, 2020 | 446.00M |
| Date | Value |
|---|---|
| September 30, 2020 | 385.00M |
| June 30, 2020 | 376.00M |
| March 31, 2020 | 404.00M |
| December 31, 2019 | 289.00M |
| September 30, 2019 | 389.00M |
| June 30, 2019 | 464.00M |
| March 31, 2019 | 508.00M |
| December 31, 2018 | 493.00M |
| September 30, 2018 | 679.00M |
| June 30, 2018 | 718.00M |
| March 31, 2018 | 714.00M |
| December 31, 2017 | 708.00M |
| September 30, 2017 | 507.00M |
| June 30, 2017 | 679.00M |
| March 31, 2017 | 667.00M |
| December 31, 2016 | 678.00M |
| September 30, 2016 | 654.00M |
| June 30, 2016 | 427.00M |
| March 31, 2016 | 400.00M |
| December 31, 2015 | 379.00M |
| September 30, 2015 | 278.00M |
| June 30, 2015 | 171.00M |
| March 31, 2015 | 83.00M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Supernus Pharmaceuticals, Inc. | 509.26M |
| Bristol Myers Squibb Co. | 7.323B |
| Eli Lilly & Co. | 12.62B |
| Ligand Pharmaceuticals, Inc. | 147.60M |
| Amneal Pharmaceuticals, Inc. | 434.04M |